COVID-19 is not a standard respiratory virus, it’s a serious threat to a number of vital organs. As medical specialists learn more about the virus and how it affects the human body, alarming complications are becoming evident including life-threatening blood clots in the lungs, heart and brain of COVID-19 patients.
Many patients with high blood pressure try to follow a healthy diet, exercise, and take medications — yet their blood pressure is still high.
A/Prof Walton is coordinating the SPYRAL Hypertension study, a multi-centre, international, randomised, interventional study, using renal denervation. The purpose of the Trial is to provide information about the safety and efficacy of the investigational Symplicity Spyral™ catheter and the Symplicity G3™ generator to help reduce blood pressure. To be eligible for the Trial, patients must be between the ages of 20 and 80 and have uncontrolled hypertension, with readings of 150-180/90mmHg.
Dr Tony Walton is Deputy Director and Head of Catheter Laboratory in the Department of Cardiology. He is a clinician, interventional cardiologist who specialises in structural heart procedures.
A/Prof Ingrid Hopper is a heart failure physician and clinical pharmacologist.